Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 5
2011 5
2012 3
2017 3
2018 1
2019 5
2020 7
2021 11
2022 4
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. Tagawa ST, et al. Among authors: jain rk. J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30. J Clin Oncol. 2021. PMID: 33929895 Free PMC article. Clinical Trial.
Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Singh AM, et al. Among authors: jain rk. BioDrugs. 2023 Jul;37(4):505-520. doi: 10.1007/s40259-023-00606-5. Epub 2023 May 31. BioDrugs. 2023. PMID: 37256534 Review.
Immunotherapy Advances in Urothelial Carcinoma.
Jain RK, Snyders T, Nandagopal L, Garje R, Zakharia Y, Gupta S. Jain RK, et al. Curr Treat Options Oncol. 2018 Dec 15;19(12):79. doi: 10.1007/s11864-018-0598-x. Curr Treat Options Oncol. 2018. PMID: 30554335 Review.
Neoadjuvant therapy for muscle-invasive bladder cancer.
Jain RK, Sonpavde G. Jain RK, et al. Expert Rev Anticancer Ther. 2020 Jul;20(7):603-614. doi: 10.1080/14737140.2020.1784011. Epub 2020 Jun 30. Expert Rev Anticancer Ther. 2020. PMID: 32546025 Review.
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. Li R, et al. Among authors: jain rk. Clin Cancer Res. 2023 Oct 2;29(19):3875-3881. doi: 10.1158/1078-0432.CCR-23-0354. Clin Cancer Res. 2023. PMID: 37505486 Clinical Trial.
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.
Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. Li R, et al. Among authors: jain rk. Front Immunol. 2021 Jun 29;12:694079. doi: 10.3389/fimmu.2021.694079. eCollection 2021. Front Immunol. 2021. PMID: 34267760 Free PMC article. Review.
Personalized medicine: the road ahead.
Mehta R, Jain RK, Badve S. Mehta R, et al. Among authors: jain rk. Clin Breast Cancer. 2011 Mar;11(1):20-6. doi: 10.3816/CBC.2011.n.004. Clin Breast Cancer. 2011. PMID: 21421518 Review.
48 results